Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 31.11% | -- |
POINT Biopharma Global Inc | 50.19% | 1.38bn |
Versanis Bio Inc | 85.98% | 1.93bn |
Emergence Therapeutics AG | 76.25% | 8.33m |
Sigilon Therapeutics Inc | 76.25% | 316.64m |
Data delayed at least 15 minutes, as of May 24 2024 00:00 BST.